Liminatus is a life sciences. Over the past three years, Liminatus has been involved in 1 licensing and acquisition transaction, with a primary focus on CAR-T (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
CAR-T
Focus Area
Mega Deals
Licensing, acquisition, and partnership transactions involving Liminatus in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| InnocsAI CAR-T platform | InnocsAI | CAR-T | Unknown | acquisition | May 2026 |
Therapeutic areas and modalities where Liminatus is most active based on deal history and clinical trial data.
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
CAR-T Benchmarks
Upfront, milestone, and royalty benchmarks for car-t deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Liminatus is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Liminatus ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Liminatus include Mega Deals (2 deals and trials). In terms of modality, Liminatus has shown particular interest in car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Liminatus and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Liminatus's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals